Gyre Therapeutics (GYRE) Other Operating Expenses (2014 - 2026)

Gyre Therapeutics (GYRE) has reported Other Operating Expenses for 11 consecutive years, with $17.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Operating Expenses rose 52.67% year-over-year to $17.9 million; the TTM figure through Mar 2026 stood at $17.9 million (up 53.5% YoY), while the FY2025 annual figure was -$4000.0, up 93.94% from the prior year.
• Other Operating Expenses advanced to $17.9 million in Q1 2026 per GYRE's latest filing, from -$2000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $57.2 million in Q2 2022 and bottomed at -$57.2 million in Q4 2022.
• Historically, Other Operating Expenses has averaged $3.3 million across 5 years, with a median of $500.0 in 2024.
• Annual changes were most pronounced in 2022 — Other Operating Expenses jumped 4925.9% — and 2025, when it plunged 200.0%.
• Gyre Therapeutics' Other Operating Expenses stood at -$57.2 million in 2022, then jumped by 96.2% to -$2.2 million in 2023, then soared by 100.09% to $2000.0 in 2024, then slumped by 200.0% to -$2000.0 in 2025, then jumped by 895900.0% to $17.9 million in 2026.
• Business Quant data shows GYRE's Other Operating Expenses at $17.9 million in Q1 2026, -$2000.0 in Q4 2025, and -$1000.0 in Q3 2025.